Navigation Links
QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
Date:11/9/2012

CHICAGO, November 9, 2012 /PRNewswire/ --

QUANTEL Medical today announced that IRIDEX and QUANTEL Medical have signed a global patent licensing agreement that gives QUANTEL access to IRIDEX MicroPulse technology. This proprietary technology provides ophthalmologists a noninvasive treatment for sight-threatening diseases of the eye, including complications associated with diabetes. Unlike conventional laser therapy, MicroPulse spares the eye tissue responsible for vision while producing comparable clinical effect to traditional methods that destroy tissue.

"There is a significant need in the market place for efficient and durable therapies for retinal diseases associated with the growth of diabetes and the aging population," stated Will Moore, IRIDEX President and CEO.  He continued, "With 10-year follow up data, a growing global user base, and significant patent protection, MicroPulse is emerging as a future standard of care." The license agreement will allow QUANTEL to market and display IRIDEX' MicroPulse technology for their range of high quality clinical lasers and is the next step in gaining broad market availability of MicroPulse photocoagulation lasers. Both QUANTEL and IRIDEX offer a full line of laser systems that offer standard photocoagulation in addition to MicroPulse laser therapy.

Moore continued, "Further establishing the MicroPulse brand and technology as an IRIDEX  property is critical as the market continues to recognize its broad applicability for retina and other procedures.  We look forward to working with others in the industry as it migrates toward a new standard for laser therapy in additional segments."  

"The global clinical evidence supporting IRIDEX' MicroPulse laser technology was an important factor in this decision", stated Mr. Jean-Marc Gendre, CEO of QUANTEL Medical.  He continued, "By aligning our market strategies with another industry leader, we believe the ophthalmic communi
'/>"/>

SOURCE QUANTEL Medical
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BURLINGTON, Mass. , June 19, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... the majority of surveyed U.S. and European rheumatologists ... of the attributes that most influences their prescribing ... U.S. and European rheumatologists, respectively, rank the percentage ...
(Date:6/19/2013)... , June 19, 2013 BD Biosciences, a segment ... ), a leading global medical technology company, today announced the ... the latest in its line of high-performance research flow cytometers. ... high-performance multicolor analysis with the most compact footprint in its ... and a height of 30" (76.2 cm). Recognizing that space ...
(Date:6/19/2013)... PRINCETON, N.J. , June 19, 2013 ... Belrose Pharma, a new specialty pharmaceutical company ... generation of innovative injectable and sustained release ... high unmet medical needs, today announced the ... (Customized Linker Technology®) platform and associated product ...
Breaking Medicine Technology:U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4
... YORK, Oct. 24, 2011 Reportlinker.com ... report is available in its catalogue: ... to 2017 - Glaucoma and Cataract ... Ophthalmic Surgery to Drive the Ophthalmic ...
... 2011 Phreesia, the patient check-in company, is committed ... practices nationwide with its electronic self-service check-in solution. One ... for practices is by automating the eligibility and benefits ... accurate billing by confirming coverage prior to the exam. ...
Cached Medicine Technology:Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 2Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 3Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 4Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 5Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 6Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 7Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 8Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 9Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 10Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 11Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 12Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 13Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 14Phreesia Continues to Enhance its Market-Leading Eligibility and Benefits Verification Process for Medical Practices 2
(Date:6/19/2013)... Quapaw, OK (PRWEB) June 19, 2013 ... of Companies, including RWI Benefits, LLC, Native Care ... The National Association of Health Underwriters’ (NAHU) new ... Affordable Care Act (PPACA). This continuing education course ... states, and Roberson will receive eleven education credits ...
(Date:6/19/2013)... According to a June 17, 2013 Allure ... is not uncommon for a person to suffer from a ... is likely to forget to reapply sunscreen properly and end ... and itchy. When this occurs, it is essential to act ... people do not realize that milk contains proteins, fats, and ...
(Date:6/19/2013)... In a major international study led by researchers at ... targeted therapy ibrutinib continues to show remarkable promise for ... (MCL). , The most recent interim findings of the ... New England Journal of Medicine . Previous interim ... American Society of Hematology Annual Meeting and Exposition. ...
(Date:6/19/2013)... Pa. (June 19, 2013) The results of three ... of Neurosurgery , official journal of the ... published by Lippincott Williams & Wilkins , a ... study indicates that continuous "machine learning" using artificial neural ... in patients with advanced brain cancers. Another study in ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
Breaking Medicine News(10 mins):Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Skin Care – How to treat Sunburn 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3
... Dec. 1 Acuo Technologies(R), developers,of high-performance software ... services, today announced the contracting with Rush,University ... new vendor neutral archiving,solution which becomes the basis ... archiving solution is based on the Acuo Technologies ...
... In recognition of World AIDS Day, Charlotte Bobcats, Emeka Okafor, will ... One Million African Lives Initiative (OMALI), a program of the Safe ... is to save one million lives in Africa by 2011 by ... , , OMALI will be ...
... TOMS Shoes, the philanthropic,footwear company, has launched a ... and Give More this holiday season. For 30,days, from ... to help give 30,000 pairs of shoes to children ... preventable by wearing shoes. By,purchasing a pair of shoes ...
... , , ANN ARBOR, ... pajamas or a video game are all quick and easy gifts to ... not give something more healthy and beneficial to a loved one? Why ... Staying healthy around the holidays can be challenging, and this ...
... Dec. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: ... administration of NGX426, an,AMPA/kainate-type glutamate receptor antagonist, ... hyperalgesia (abnormally increased,pain state) and allodynia (pain ... compared to placebo following intradermal injections of ...
... Horvath, D.V.M., as Vice President of Preclinical Sciences and ... , CAMBRIDGE, Mass., Dec. ... Mass.-based executive team with the appointment of Jeffrey T. ... announced the additions of Christopher Horvath, D.V.M., as vice ...
Cached Medicine News:Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 2Health News:Acuo Technologies Announces Vendor Neutral Archiving Contract With Rush University Medical Center 3Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 2Health News:Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer 3
... to provide excellent protection and ease of ... being closer to an adhesive in molecular ... CoEase to maintain viscosity at high shear ... worlds for superb performance during capsulorhexis, phaco, ...
... viscosurgical device is a cohesive ... high molecular weight, high pseudoplasticity, ... provides excellent space maintenance, facilitates ... removed. It is available in ...
... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...
... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...
Medicine Products: